Key Documents

View All Documentation

SML2156

Erlotinib hydrochloride

Name: Erlotinib hydrochloride
Brand: SIGMA

≥98% (HPLC), EGFR kinase inhibitor, powder

Synonym(s):

774 hydrochloride, CP-358, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, OSI-744 hydrochloride

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₂H₂₃N₃O₄ · HCl

CAS Number:

183319-69-9

Molecular Weight:

429.90

UNSPSC Code:

12352200

NACRES:

NA.77

MDL number:

MFCD07781272

Assay:

≥98% (HPLC)

Form:

powder

Storage condition:

desiccated

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Erlotinib hydrochloride, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

−20°C

SMILES string

Cl.N(c3cc(ccc3)C#C)c1ncnc2c1cc(c(c2)OCCOC)OCCOC

InChI

1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H

InChI key

GTTBEUCJPZQMDZ-UHFFFAOYSA-N

Description

General description

Erlotinib hydrochloride is an antineoplastic drug. It regulates mechanistic target of rapamycin (mTOR) inhibition, epidermal growth factor receptor down-regulation and epidermal interstitial transformation (EMT) suppression.

Application

Erlotinib hydrochloride has been used to activate mitochondrial fragmentation in a human PANC-1 pancreatic cancer cell line.

Biochem/physiol Actions

EGFR kinase inhibitor; Antineoplastic

Erlotinib hydrochloride is an inhibitor of the receptor tyrosine kinase EGFR (epidermal growth factor receptor). It is used clinically for the treatment of non-small cell lung cancer (NSCLC) and in combination for metastatic pancreatic cancer.

Still not finding the right product?

Explore all of our products under Erlotinib hydrochloride

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Dual stimuli-responsive release of aptamer AS1411 decorated erlotinib loaded chitosan nanoparticles for non-small-cell lung carcinoma therapy.

Kandasamy Saravanakumar et al.

Carbohydrate polymers, 245, 116407-116407 (2020-07-29)

The present work was developed the pH dependent-aptamer AS1411 (APT) decorated and erlotinib (En) loaded chitosan nanoparticles (CSNPs) for promising non-small-cell lung carcinoma (NSCLC) treatment. The characterization studies revealed that formulated APT-En-CSNPs were spherical in shape with size of 165.95

Analytical Methods for Therapeutic Drug Monitoring and Toxicology (2011)

Simultaneous inhibition of IGF1R and EGFR enhances the efficacy of standard treatment for colorectal cancer by the impairment of DNA repair and the induction of cell death.

Rabea Oberthür et al.

Cancer letters, 407, 93-105 (2017-08-22)

Overexpression and activation of receptor tyrosine kinases (RTKs), such as the insulin-like growth factor 1 receptor (IGF1R) and the epidermal growth factor receptor (EGFR), are frequent phenomena in colorectal cancer (CRC). Here, we evaluated the effect and the cellular mechanisms

View All Related Papers

Global Trade Item Number

SKU	GTIN
SML2156-100MG	04061835502981
SML2156-50MG	04061835502974